Is Bicycle Therapeutics Stock a Good Investment?
Bicycle Therapeutics Investment Advice | BCYC |
- Examine Bicycle Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bicycle Therapeutics' leadership team and their track record. Good management can help Bicycle Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Bicycle Therapeutics' business and its evolving consumer preferences.
- Compare Bicycle Therapeutics' performance and market position to its competitors. Analyze how Bicycle Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Bicycle Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bicycle Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bicycle Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bicycle Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Bicycle Therapeutics Stock
Researching Bicycle Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 92.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bicycle Therapeutics recorded a loss per share of 2.9. The entity had not issued any dividends in recent years.
To determine if Bicycle Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bicycle Therapeutics' research are outlined below:
| Bicycle Therapeutics generated a negative expected return over the last 90 days | |
| Bicycle Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 35.27 M. Net Loss for the year was (169.03 M) with loss before overhead, payroll, taxes, and interest of (137.69 M). | |
| Bicycle Therapeutics currently holds about 372.77 M in cash with (164.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.56, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Bicycle Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are held by institutions such as insurance companies |
Bicycle Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bicycle Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bicycle Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Bicycle Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 628.36 M.Basic technical analysis of Bicycle Stock
As of the 24th of March, Bicycle Therapeutics shows the mean deviation of 2.55, and Risk Adjusted Performance of (0.18). Bicycle Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Bicycle Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bicycle Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bicycle Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bicycle Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bicycle Therapeutics' Outstanding Corporate Bonds
Bicycle Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bicycle Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bicycle bonds can be classified according to their maturity, which is the date when Bicycle Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Bicycle Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bicycle Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.18) | |||
| Market Risk Adjusted Performance | 1.31 | |||
| Mean Deviation | 2.55 | |||
| Coefficient Of Variation | (488.90) | |||
| Standard Deviation | 3.45 | |||
| Variance | 11.93 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (0.58) | |||
| Treynor Ratio | 1.3 | |||
| Maximum Drawdown | 21.3 | |||
| Value At Risk | (6.07) | |||
| Potential Upside | 4.19 | |||
| Skewness | 1.14 | |||
| Kurtosis | 4.19 |
| Risk Adjusted Performance | (0.18) | |||
| Market Risk Adjusted Performance | 1.31 | |||
| Mean Deviation | 2.55 | |||
| Coefficient Of Variation | (488.90) | |||
| Standard Deviation | 3.45 | |||
| Variance | 11.93 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (0.58) | |||
| Treynor Ratio | 1.3 | |||
| Maximum Drawdown | 21.3 | |||
| Value At Risk | (6.07) | |||
| Potential Upside | 4.19 | |||
| Skewness | 1.14 | |||
| Kurtosis | 4.19 |
Consider Bicycle Therapeutics' intraday indicators
Bicycle Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bicycle Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 35321.33 | |||
| Daily Balance Of Power | 0.2553 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 9.12 | |||
| Day Typical Price | 9.14 | |||
| Price Action Indicator | 0.14 | |||
| Period Momentum Indicator | 0.12 |
Bicycle Stock media impact
Far too much social signal, news, headlines, and media speculation about Bicycle Therapeutics that are available to investors today. That information is available publicly through Bicycle media outlets and privately through word of mouth or via Bicycle internal channels. However, regardless of the origin, that massive amount of Bicycle data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bicycle Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bicycle Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bicycle Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bicycle Therapeutics alpha.
Bicycle Therapeutics Corporate Management
| Kevin MBA | CEO Director | Profile | |
| CBE FMedsci | NonEx CoFounder | Profile | |
| Christian Heinis | Scientific Founder | Profile | |
| Stephanie Yao | Senior Communications | Profile | |
| Alistair Milnes | Chief Officer | Profile | |
| Gillian Langford | Head Management | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bicycle Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicycle Therapeutics. If investors know Bicycle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bicycle Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bicycle Therapeutics is measured differently than its book value, which is the value of Bicycle that is recorded on the company's balance sheet. Investors also form their own opinion of Bicycle Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicycle Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicycle Therapeutics' market value can be influenced by many factors that don't directly affect Bicycle Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Bicycle Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Bicycle Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bicycle Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.